Stromal matrix metalloproteinase 2 regulates collagen expression and promotes the outgrowth of experimental metastases

Journal of Pathology

Volumn 235, Issue 5, 2015, Pages 773-783

  Bates, Andreia L ^a   Pickup, Michael W ^a,c   Hallett, Miranda A ^a   Dozier, E Ashley ^a   Thomas, Stacy ^b   Fingleton, Barbara ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TENNESSEE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

breast cancer; collagen I; collagen IV; fibroblasts; MMP2; proliferation; pulmonary metastasis

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; GELATINASE A; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA1; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; MMP2 PROTEIN, HUMAN; MMP2 PROTEIN, MOUSE; TGFB1 PROTEIN, MOUSE; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LASER CAPTURE MICRODISSECTION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR GROWTH; WILD TYPE; ANIMAL; C57BL MOUSE; DEFICIENCY; ENZYMOLOGY; EXPERIMENTAL MAMMARY NEOPLASM; FIBROBLAST; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; KNOCKOUT MOUSE; LUNG TUMOR; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; SECONDARY; TIME FACTOR;

ACTINS; ANIMALS; CELL PROLIFERATION; COCULTURE TECHNIQUES; COLLAGEN; FEMALE; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 2; MICE, INBRED C57BL; MICE, KNOCKOUT; SPHEROIDS, CELLULAR; STROMAL CELLS; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

EID: 84924624912     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4493     Document Type: Article

References (63)

1. Greenberg PA, Hortobagyi GN, Smith TL, et al,. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205.
2. Cancer SA,. Cancer Facts and Figures 2013. American Cancer Society: Atlanta, GA, 2013.
3. Talmadge JE, Fidler IJ,. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010; 70: 5649-5669.
4. Valastyan S, Weinberg RA,. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-292.
5. Vanharanta S, Massague J,. Origins of metastatic traits. Cancer Cell 2013; 24: 410-421.
6. Deryugina EI, Quigley JP,. Matrix metalloproteinases and tumor metastasis. Cancer Metast Rev 2006; 25: 9-34.
7. Malemud CJ,. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006; 11: 1696-1701.
8. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-867.
9. Egeblad M, Werb Z,. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
10. Kessenbrock K, Plaks V, Werb Z,. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
11. Pacheco MM, Mourao M, Mantovani EB, et al,. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metast 1998; 16: 577-585.
12. Murashige M, Miyahara M, Shiraishi N, et al,. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol 1996; 26: 303-309.
13. Nomura H, Fujimoto N, Seiki M, et al,. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 1996; 69: 9-16.
14. Liu SC, Yang SF, Yeh KT, et al,. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta 2006; 371: 92-96.
15. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T,. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003; 89: 1270-1275.
16. Hirvonen R, Talvensaari-Mattila A, Paakko P, et al,. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res Treat 2003; 77: 85-91.
17. Nelson AR, Fingleton B, Rothenberg ML, et al,. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-1149.
18. Toi M, Ishigaki S, Tominaga T,. Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat 1998; 52: 113-124.
19. Heppner KJ, Matrisian LM, Jensen RA, et al,. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273-282.
20. Polette M, Gilbert N, Stas I, et al,. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch 1994; 424: 641-645.
21. Ito A, Nakajima S, Sasaguri Y, et al,. Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer 1995; 71: 1039-1045.
22. Noel A, Nusgens B, Lapiere CH, et al,. Interactions between tumoral MCF7 cells and fibroblasts on matrigel and purified laminin. Matrix 1993; 13: 267-273.
23. Noel A, Hajitou A, L'Hoir C, et al,. Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer 1998; 76: 267-273.
24. Itoh T, Tanioka M, Yoshida H, et al,. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048-1051.
25. Martin MD, Carter KJ, Jean-Philippe SR, et al,. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 2008; 68: 6251-6259.
26. Pickup MW, Laklai H, Acerbi I, et al,. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas. Cancer Res 2013; 73: 5336-5346.
27. Duffield JS, Lupher M, Thannickal VJ, et al,. Host responses in tissue repair and fibrosis. Annu Rev Pathol 2013; 8: 241-276.
28. Paunescu V, Bojin FM, Tatu CA, et al,. Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J Cell Mol Med 2011; 15: 635-646.
29. + myeloid cells that promote invasion. Nat Genet 2007; 39: 467-475.
30. Mantovani A, Schioppa T, Porta C, et al,. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metast Rev 2006; 25: 315-322.
31. Zhou Y, Hagood JS, Murphy-Ullrich JE,. Thy-1 expression regulates the ability of rat lung fibroblasts to activate transforming growth factor-β in response to fibrogenic stimuli. Am J Pathol 2004; 165: 659-669.
32. Kis K, Liu X, Hagood JS,. Myofibroblast differentiation and survival in fibrotic disease. Expert Rev Mol Med 2011; 13: e27.
33. Sorrell JM, Caplan AI,. Fibroblasts-a diverse population at the center of it all. Int Rev Cell Mol Biol 2009; 276: 161-214.
34. Orimo A, Gupta PB, Sgroi DC, et al,. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
35. Baker BM, Chen CS,. Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues. J Cell Sci 2012; 125: 3015-3024.
36. Beningo KA, Dembo M, Wang YL,. Responses of fibroblasts to anchorage of dorsal extracellular matrix receptors. Proc Natl Acad Sci USA 2004; 101: 18024-18029.
37. Chang HY, Sneddon JB, Alizadeh AA, et al,. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2: E7.
38. Yeung T, Georges PC, Flanagan LA, et al,. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. Cell Motil Cytoskel 2005; 60: 24-34.
39. Olsen AL, Bloomer SA, Chan EP, et al,. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am J Physiol Gastrointest Liver Physiol 2011; 301: G110-118.
40. Huang X, Yang N, Fiore VF, et al,. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol 2012; 47: 340-348.
41. Rasanen K, Vaheri A,. Activation of fibroblasts in cancer stroma. Exp Cell Res 2010; 316: 2713-2722.
42. Desmouliere A, Geinoz A, Gabbiani F, et al,. Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122: 103-111.
43. Ronnov-Jessen L, Petersen OW,. Induction of α-smooth muscle actin by transforming growth factor-β1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 1993; 68: 696-707.
44. Pickup M, Novitskiy S, Moses HL,. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 2013; 13: 788-799.
45. Thiolloy S, Edwards JR, Fingleton B, et al,. An osteoblast-derived proteinase controls tumor cell survival via TGF-β activation in the bone microenvironment. PLoS One 2012; 7: e29862.
46. Knudsen ES, Ertel A, Davicioni E, et al,. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat 2012; 133: 1009-1024.
47. Poulsom R, Hanby AM, Pignatelli M, et al,. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 1993; 46: 429-436.
48. Provenzano PP, Inman DR, Eliceiri KW, et al,. Collagen density promotes mammary tumor initiation and progression. BMC Med 2008; 6: 11.
49. Perry SW, Schueckler JM, Burke K, et al,. Stromal matrix metalloprotease-13 knockout alters collagen I structure at the tumor-host interface and increases lung metastasis of C57BL/6 syngeneic E0771 mammary tumor cells. BMC Cancer 2013; 13: 411.
50. Franco OE, Jiang M, Strand DW, et al,. Altered TGFβ signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 2011; 71: 1272-1281.
51. Hori Y, Kashimoto T, Yonezawa T, et al,. Matrix metalloproteinase-2 stimulates collagen-I expression through phosphorylation of focal adhesion kinase in rat cardiac fibroblasts. Am J Physiol Cell Physiol 2012; 303: C947-953.
52. Liu S, Xu SW, Kennedy L, et al,. FAK is required for TGFβ-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype. Mol Biol Cell 2007; 18: 2169-2178.
53. Eldred JA, Hodgkinson LM, Dawes LJ, et al,. MMP2 activity is critical for TGFβ2-induced matrix contraction-implications for fibrosis. Invest Ophthalmol Vis Sci 2012; 53: 4085-4098.
54. Alowami S, Troup S, Al-Haddad S, et al,. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 2003; 5: R129-135.
55. Li T, Sun L, Miller N, et al,. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 343-349.
56. McCormack VA, dos Santos Silva I,. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159-1169.
57. Jensen BV, Johansen JS, Skovsgaard T, et al,. Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer. Int J Cancer 2002; 98: 582-589.
58. Brown LF, Guidi AJ, Schnitt SJ, et al,. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999; 5: 1041-1056.
59. Ramaswamy S, Ross KN, Lander ES, et al,. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54.
60. Onozuka I, Kakinuma S, Kamiya A, et al,. Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. Biochem Biophys Res Commun 2011; 406: 134-140.
61. Takamiya Y, Fukami K, Yamagishi S, et al,. Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. Nephrol Dial Transpl 2013; 28: 55-62.
62. Coussens LM, Fingleton B, Matrisian LM,. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
63. Fingleton B., Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007; 13: 333-346.